Another Phase 1b clinical trial reported that the selective ERK1/2 inhibitor, MK-8353, demonstrated substantial therapeutic efficacy both as monotherapy and in combination treatments in BRAF V600-mutated melanoma. This evidence concerns the gene MAPK3 and melanoma.